The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Miravirsen dosing in chronic hepatitis C patients results in decreased micro RNA‐122 levels without affecting other micro RNA s in plasma
Open accessAbstract
Summary: Background: Micro RNA‐122 (miR‐122) is an important host factor for hepatitis C virus replication. Administration of miravirsen, an anti‐miR‐122 oligonucleotide, resulted in a dose dependent and prolonged decrease in HCV RNA levels in chronic hepatitis C patients. Aim: To assess the plasma level of various mi RNA s in patients dosed with miravirsen. Methods: We included 16 of 36 chronic hepatitis C patients who received five injections of either 3 mg/kg (n = 4), 5 mg/kg (n = 4), 7 mg/kg (n = 4) miravirsen or placebo (n = 4) over a 4‐week period in a double‐blind, randomised phase 2a study. Plasma levels of 179 mi RNA s were determined by qPCR and compared between patients dosed with miravirsen or placebo. Results: Median plasma miR‐122 level at baseline in patients receiving miravirsen was 3.9 × 10 3 compared to 1.3 × 10 4 copies/4 μL in placebo‐dosed patients (P = 0.68). At week 1, 4, 6 and 10/12, patients dosed with miravirsen had respectively a median 72‐fold, 174‐fold, 1109‐fold and 552‐fold lower expression of miR‐122 than at baseline (P = 0.001, as compared to patients receiving placebo). At week 4 of dosing, mi RNA‐profiling demonstrated a significant lower expression of miR‐210 and miR‐532‐5p compared to baseline (3.0 and 4.7‐fold lower respectively). However, subsequent longitudinal analysis showed no significant differences in miR‐210 and miR‐532‐5p plasma levels throughout the study period. Conclusions: We demonstrated a substantial and prolonged decrease in plasma miR‐122 levels in patients dosed with miravirsen. Plasma levels of other mi RNA s were not significantly affected by antagonising miR‐122.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Wightman, B., Ha, I., & Ruvkun, G. (1993) · Cell · doi:10.1016/0092-8674(93)90530-4 · Cited by 4,292
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082
Cited by
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Metadata
- Authors
- van der Ree, M. H., van der Meer, A. J., van Nuenen, A. C., de Bruijne, J., Ottosen, S., Janssen, H. L., Kootstra, N. A., & Reesink, H. W.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2015-10-26
- Volume
- 43
- Issue
- 1
- Pages
- 102-113
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1911381531
- Cited by
- 159
- References
- 4
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Miravirsen dosing in chronic hepatitis C patients results in decreased micro RNA‐122 levels without affecting other micro RNA s in plasma. https://app.cochat.ai/papers/10.1111/apt.13432
- The paper
- van der Ree, M. H., van der Meer, A. J., van Nuenen, A. C., de Bruijne, J., Ottosen, S., Janssen, H. L., Kootstra, N. A., & Reesink, H. W. (2016). Miravirsen dosing in chronic hepatitis C patients results in decreased micro RNA‐122 levels without affecting other micro RNA s in plasma. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.13432
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.